Skip to main content
OpenTrials
Completed

NCT Number: NCT02183220

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients between 18 and 65 years old
  • Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
  • At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
  • The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
  • First episodic headache occurred at an age under 50 years
  • Written informed consent according to Good Clinical Practice (GCP) and local regulations
  • The patient was able to fill in the Patient's Diary

Exclusion criteria

  • The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
  • The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
  • The patient has more than 15 episodes of tension headache per month
  • Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
  • Concomitant treatment with (non-) prescriptional analgesics
  • Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
  • Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
  • Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
  • Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
  • Concomitant treatment with any drug containing ASA and/or metamizol
  • Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
  • Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
  • Female patients in child-bearing age not using adequate means of birth control
  • Pregnancy and/or lactation
  • Gastrointestinal ulcers
  • Liver and/or renal disease
  • Bronchial asthma
  • Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Patients with active gastroesophageal flux disease (Amendment number 1)
  • Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)

Treatment and study plan

Metamizol

Drug

Acetylsalicylic acid (ASA)

Drug

Metamizol placebo

Drug

ASA placebo

Drug

Primary outcomes

  1. Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

Secondary outcomes

  1. Pain intensity difference (PID) on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  2. Maximum pain intensity difference (MAXPID) on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  3. Number of patients with at least a 50% pain reduction on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  4. Time to 50% pain intensity reduction on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  5. Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)

    Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake

  6. Total pain relief (TOTPAR) on a VRS

    Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake

  7. Number of patients using rescue medication

    Time frame: 2, 3, and 4 hours after drug intake

  8. Global efficacy assessment on a VRS by the patient and investigator

    Time frame: 4 hours after drug intake

  9. Number of patients with adverse events

    Time frame: up to 2 months

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.

Important dates

Study start
1998
Primary completion
1999
First posted
Jul 8, 2014
Registry last updated
Jul 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.